Shenzhen Jifu Pharmaceutical Co., Ltd.

Main purpose To compare the differences in the extent and rate of absorption of ursodeoxycholic acid capsules (250 mg/capsule) produced by Shenzhen Zifu Pharmaceutical Co., Ltd. and ursodeoxycholic acid capsules (250 mg/capsule, trade name: Ursofalk®) certified by Dr. Falk Pharma GmbH in healthy adults under fasting and postprandial administration conditions, and to evaluate their bioequivalence. Secondary purpose To evaluate the safety of ursodeoxycholic acid capsules (250 mg/capsule) produced by Shenzhen Zifu Pharmaceutical Co., Ltd. and the reference preparation Ursofalk® (250 mg/capsule) under fasting and postprandial administration conditions.

Main purpose: To investigate the oral administration of the test preparation and reference preparation of ursodeoxycholic acid tablets to healthy subjects under fasting and postprandial conditions, to compare the blood drug concentration and pharmacokinetic parameters of the two preparations in humans, and to evaluate whether the two preparations are bioequivalent in healthy subjects. Secondary purpose: To observe the safety of the test preparation and reference preparation in healthy subjects.